Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20264778 | 0.91 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16094707 | 0.84 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16121716 | 0.79 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16103339 | 0.78 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL19342013 | 0.77 | RAF1 (0.90) | RAF1BRAF | |
| SCHEMBL16121374 | 0.76 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16103475 | 0.75 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL20264632 | 0.75 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL16101330 | 0.73 | RAF1 (1.00) | RAF1BRAF | |
| SCHEMBL20264788 | 0.72 | RAF1 (1.00) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191478-B1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| EP-3191478-B1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | NOVARTIS AG (CH) | 2019-01-01 | — | — | US | disclosed |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | NOVARTIS AG (CH) | 2019-01-01 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885 |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.